Ghent University Academic Bibliography

Advanced

Predicting outcomes for children with neuroblastoma

Joëlle Vermeulen UGent, Katleen De Preter UGent, Pieter Mestdagh UGent, Genevieve Laureys UGent, Franki Speleman UGent and Jo Vandesompele UGent (2010) DISCOVERY MEDICINE. 10(50). p.29-36
abstract
One of the main challenges in clinical cancer research remains to be accurate outcome prediction at the time of diagnosis. Although not frequent in absolute terms, neuroblastoma represents an important clinical challenge, as it is fatal in almost half of the patients despite advances in multimodal anti-cancer therapies. Four major risk stratification systems for neuroblastoma patients are currently being used in various parts of the world. Systems are based on a combination of various clinical, histopathological, and biological factors. Accordingly, different therapeutic schemes exist ranging from wait-and-see approaches to intensive multimodal therapies. Clinical experience with the currently used risk stratification systems suggests that the stratification of patients for treatment is useful, but patients with the same clinico-pathological parameters, receiving the same treatment, can have markedly different clinical courses. Therefore, the challenge remains to identify additional tumor-specific and sensitive prognostic markers for improved risk estimation at the time of diagnosis and to improve the choice of risk-related therapy. Various studies have put forward new prognostic markers, including copy number aberrations, gene expression signatures, and epigenetic markers.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
HIGH-RISK NEUROBLASTOMA, EXPRESSION-BASED CLASSIFICATION, CHROMOSOME ARM 17Q, GENE-EXPRESSION, N-MYC, PROGNOSIS, AMPLIFICATION, TUMORS, PHENOTYPE, SYSTEM
journal title
DISCOVERY MEDICINE
Discov. Med.
volume
10
issue
50
pages
29 - 36
Web of Science type
Article
Web of Science id
000208638400004
ISSN
1539-6509
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1199600
handle
http://hdl.handle.net/1854/LU-1199600
alternative location
http://www.discoverymedicine.com/Joelle-Vermeulen/2010/07/08/predicting-outcomes-for-children-with-neuroblastoma/
date created
2011-03-30 15:40:49
date last changed
2017-04-07 14:29:25
@article{1199600,
  abstract     = {One of the main challenges in clinical cancer research remains to be accurate outcome prediction at the time of diagnosis. Although not frequent in absolute terms, neuroblastoma represents an important clinical challenge, as it is fatal in almost half of the patients despite advances in multimodal anti-cancer therapies. Four major risk stratification systems for neuroblastoma patients are currently being used in various parts of the world. Systems are based on a combination of various clinical, histopathological, and biological factors. Accordingly, different therapeutic schemes exist ranging from wait-and-see approaches to intensive multimodal therapies. Clinical experience with the currently used risk stratification systems suggests that the stratification of patients for treatment is useful, but patients with the same clinico-pathological parameters, receiving the same treatment, can have markedly different clinical courses. Therefore, the challenge remains to identify additional tumor-specific and sensitive prognostic markers for improved risk estimation at the time of diagnosis and to improve the choice of risk-related therapy. Various studies have put forward new prognostic markers, including copy number aberrations, gene expression signatures, and epigenetic markers.},
  author       = {Vermeulen, Jo{\"e}lle and De Preter, Katleen and Mestdagh, Pieter and Laureys, Genevieve and Speleman, Franki and Vandesompele, Jo},
  issn         = {1539-6509},
  journal      = {DISCOVERY MEDICINE},
  keyword      = {HIGH-RISK NEUROBLASTOMA,EXPRESSION-BASED CLASSIFICATION,CHROMOSOME ARM 17Q,GENE-EXPRESSION,N-MYC,PROGNOSIS,AMPLIFICATION,TUMORS,PHENOTYPE,SYSTEM},
  language     = {eng},
  number       = {50},
  pages        = {29--36},
  title        = {Predicting outcomes for children with neuroblastoma},
  url          = {http://www.discoverymedicine.com/Joelle-Vermeulen/2010/07/08/predicting-outcomes-for-children-with-neuroblastoma/},
  volume       = {10},
  year         = {2010},
}

Chicago
Vermeulen, Joëlle, Katleen De Preter, Pieter Mestdagh, Genevieve Laureys, Franki Speleman, and Jo Vandesompele. 2010. “Predicting Outcomes for Children with Neuroblastoma.” Discovery Medicine 10 (50): 29–36.
APA
Vermeulen, Joëlle, De Preter, K., Mestdagh, P., Laureys, G., Speleman, F., & Vandesompele, J. (2010). Predicting outcomes for children with neuroblastoma. DISCOVERY MEDICINE, 10(50), 29–36.
Vancouver
1.
Vermeulen J, De Preter K, Mestdagh P, Laureys G, Speleman F, Vandesompele J. Predicting outcomes for children with neuroblastoma. DISCOVERY MEDICINE. 2010;10(50):29–36.
MLA
Vermeulen, Joëlle, Katleen De Preter, Pieter Mestdagh, et al. “Predicting Outcomes for Children with Neuroblastoma.” DISCOVERY MEDICINE 10.50 (2010): 29–36. Print.